Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
Corinna Kosnopfel(University of Tübingen), Birgit Schittek(Hertie Institute for Clinical Brain Research)
Cited by 48
Related Papers
β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance
|PLoS ONE|2011|108
Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition
|Cell Death and Disease|2020|29
Histological and functional characterization of 3D human skin models mimicking the inflammatory skin diseases psoriasis and atopic dermatitis
|Disease Models & Mechanisms|2024|18
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
|Cancer Research Communications|2023|15
<scp>PARP1</scp> expression predicts <scp>PARP</scp> inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma
|International Journal of Cancer|2024|12